Study to Evaluate Markers of Response in Locally Advanced Breast Cancer

Exclusion Criteria

• •Metastatic disease
• •Inadequate health to receive the study chemotherapy
• •Previous breast cancer treatment
• •Pregnant or lactating women
• •Major surgery or significative traumatic injure in the 28 days previous to inclusion, or during treatment.
• •Minor surgery 24 hours before first bevacizumab infusion
• •Concomitant or recent aspirin(\>325mg/day)or clopidogrel(\>75mg/day) treatment
• •Concomitant or recent oral anticoagulant treatment
• •History or evidence or bleeding diathesis or hereditary coagulopathy with bleeding risk
• •Uncontrolled arterial hypertension
• •Clinical significative heart disease, or uncontrolled severe arrhythmia disorder
• •Unhealed wounds, peptic ulcer or bone fracture
• •History of abdominal fistula, gastrointestinal perforation or intrabdominal abscess, 6 months before inclusion
• •Evidence of any other disease, neurological or metabolical disorder or physical examination or laboratory finding related with any disease that makes the subjet ineligible for the study treatment or that put the subject in risk because of the study treatment.
• •Psychiatric disorders that may prevent the subject to complete the study treatment
• •Current participation in any other trial involving an investigational drug, or participation in any kind of trial 28 days before inclusion
• •Chronical corticosteroid treatment
• •Hypersensitivity reaction to bevacizumab or any of its components or any of the other study drugs or components
• •Patients diagnosed with different neoplasms the previous 5 years excluding non melanoma skin cancer and resected cervical cancer